Eurich Dean T, Marrie Thomas J, Johnstone Jennie, Majumdar Sumit R
Department of Public Health Sciences, School of Public Health, University of Alberta, 13-103 Clinical Sciences Bldg., Edmonton, AB, T6G 2G3 Canada.
Am J Respir Crit Care Med. 2008 Sep 1;178(5):527-33. doi: 10.1164/rccm.200802-282OC. Epub 2008 Jun 12.
Observational studies suggest a 50% mortality reduction for older patients receiving influenza vaccination; some deem this magnitude of benefit implausible and invoke confounding by the "healthy user effect" as an alternate explanation.
To evaluate unrecognized confounding by hypothesizing the presence of a 50% mortality reduction with vaccination for patients with pneumonia outside of influenza season.
Clinical, laboratory, and functional data were prospectively collected on 1,813 adults with community-acquired pneumonia admitted to six hospitals outside of influenza season in the Capital Health region (AB, Canada). Vaccination status was ascertained by interview and chart review. Outcome was in-hospital mortality. Influenza-vaccinated patients were matched to a nonvaccinated control using propensity scores, and then multivariable regression was used to determine the independent association between vaccination and mortality.
The cohort consisted of 352 vaccine recipients and 352 matched control subjects. Most (85%) patients were 65 years or older, 29% had severe pneumonia, and 12% died. Influenza vaccination was associated with a 51% mortality reduction (28 of 352 [8%] died vs. 53 of 352 [15%] control subjects; unadjusted odds ratio [OR], 0.49; 95% confidence interval [CI], 0.30-0.79; P = 0.004) outside influenza season. Adjustment for age, sex, and comorbidities did not alter these findings (adjusted OR, 0.45; 95% CI, 0.27-0.76). More complete adjustment for confounding (e.g., functional and socioeconomic status) markedly attenuated these benefits and their statistical significance (adjusted OR, 0.81; 95% CI, 0.35-1.85; P = 0.61).
The 51% reduction in mortality with vaccination initially observed in patients with pneumonia who did not have influenza was most likely a result of confounding. Previous observational studies may have overestimated mortality benefits of influenza vaccination.
观察性研究表明,接种流感疫苗的老年患者死亡率降低了50%;一些人认为这种益处程度令人难以置信,并援引“健康使用者效应”导致的混杂因素作为另一种解释。
通过假设在流感季节之外肺炎患者接种疫苗可使死亡率降低50%,来评估未被识别的混杂因素。
前瞻性收集了加拿大首都地区(AB省)六家医院在流感季节之外收治的1813例社区获得性肺炎成年患者的临床、实验室和功能数据。通过访谈和病历审查确定疫苗接种状况。结局指标为住院死亡率。使用倾向得分将接种流感疫苗的患者与未接种疫苗的对照进行匹配,然后采用多变量回归确定疫苗接种与死亡率之间的独立关联。
该队列由352名疫苗接种者和352名匹配的对照对象组成。大多数(85%)患者年龄在65岁及以上,29%患有重症肺炎,12%死亡。在流感季节之外,流感疫苗接种与死亡率降低51%相关(352例中有28例[8%]死亡,而352例对照对象中有53例[15%]死亡;未调整的比值比[OR]为0.49;95%置信区间[CI]为0.30 - 0.79;P = 0.004)。对年龄、性别和合并症进行调整并未改变这些结果(调整后的OR为0.45;95%CI为0.27 - 0.76)。对混杂因素进行更全面的调整(如功能和社会经济状况)显著减弱了这些益处及其统计学意义(调整后的OR为0.81;95%CI为0.35 - 1.85;P = 0.61)。
最初在非流感肺炎患者中观察到的接种疫苗使死亡率降低51%很可能是混杂因素导致的结果。既往观察性研究可能高估了流感疫苗接种的死亡率益处。